BioSpace News Archive

Alignment Healthcare, Inc. (NASDAQ: ALHC), a tech-enabled Medicare Advantage company, today announced that John Kao, founder and CEO, and Thomas Freeman, chief financial officer, will participate in the Morgan Stanley 21st Annual Global Healthcare Conference, being held in New York, New York, including a presentation on Wednesday, Sept. 13, at 1:35 p.m. EDT.

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a publication in Nature Communications demonstrating the utility of optical genome mapping (OGM) as an alternative to karyotyping (KT) and chromosomal microarray (CMA) for the evaluation of CRISPR-Cas9 edited human induced pluripotent stem cell (iPSC) lines in order to uncover possible pathogenic structural alterations that may limit their usefulness for stem cell therapy.

PTC Therapeutics, Inc. announced that the company will present a company overview at the following conferences.

Biotricity Inc. reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth by over eight percent from the previously announced $13 million run rate.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Company’s De Novo request for the TAEUS liver system has advanced to substantive review with the U.S. Food and Drug Administration (FDA).

Clene Inc announced that it will participate in the following investor conferences in September.

Spiral Therapeutics, Inc., a clinical-stage company focused on delivering therapies for inner ear disorders, announced a new round of financing led by Esperante Ventures and Ferring Ventures SA.

Veru Inc. (NASDAQ: VERU) today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the H.C. Wainwright 25th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on Monday, September 11th, 2023 at 9:00 a.m. ET.

Jaguar Health, Inc. announced that an article about the company’s focus on developing its novel plant-based prescription drug crofelemer for two rare disease indications, short bowel syndrome and microvillus inclusion disease, was published August 23, 2023 in The Science Times.

DexCom, Inc. announced that management will present an update on the company at the following upcoming investor conferences: Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present on behalf of the company at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6, 2023 at 3:45pm.